SCHEMBL7148525

SCHEMBL7148525

COC(=O)c1ccccc1NC(=O)CNCC(=O)C1CC(S)CN1S(C)(=O)=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.53
ACE P12821 1/20 0.53
ECE1 P42892 1/20 0.53
ALDH1A1 P00352 8/20 0.47
KDM4E B2RXH2 5/20 0.47
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
HTT P42858 1/20 0.44
HSD17B10 Q99714 5/20 0.43
TSHR P16473 3/20 0.43
MAPK10 P53779 1/20 0.43
POLB P06746 1/20 0.42
MEN1 O00255 1/20 0.42
AHR P35869 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TP53 P04637 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150551 0.85 ECE1 (0.75) MMEACEECE1ALDH1A1KDM4E
SCHEMBL7148539 0.83 MME (0.75) MMEACEECE1ALDH1A1KDM4E
SCHEMBL7144822 0.83 MME (0.75) MMEACEECE1ALDH1A1KDM4E
SCHEMBL7135286 0.81 GAA (0.47) MMEACEECE1ALDH1A1KDM4E
SCHEMBL7140017 0.77 MME (0.54) MMEACEECE1ALDH1A1KDM4E
SCHEMBL7139222 0.70 ECE1 (1.00) MMEACEECE1ALDH1A1KDM4E
SCHEMBL7150559 0.70 ECE1 (1.00) MMEACEECE1ALDH1A1KDM4E
SCHEMBL12756997 0.68 KMT2A (0.64) ALDH1A1KDM4EKMT2ASMN1; SMN2HTT
SCHEMBL7148170 0.68 MAPT (0.53) ALDH1A1KMT2ASMN1; SMN2HTTTSHR
SCHEMBL7144753 0.67 KMT2A (0.76) ALDH1A1KDM4EKMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MME 99/4885ACE 44/4885ECE1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.